Aldeyra acquires Helio Vision

Aldeyra Therapeutics has acquired the biotechnology company Helio Vision, according to a press release.
The acquisition adds Helio’s ADX-2191, intravitreal methotrexate, a phase 3 product candidate for the treatment of proliferative vitreoretinopathy, to Aldeyra’s pipeline.
ADX-2191 previously received orphan drug designation from the FDA.
“Helio Vision’s unique approach is at the crosshairs of our areas of expertise, leveraging an immunological mechanism that diminishes inflammation and cell proliferation, an orphan indication addressing a significant unmet medical need,

Full Story →